Tempest Takes China-Linked CAR-T License After Early Multiple Myeloma Data
Tempest Therapeutics, Inc. has exercised an option under its agreement with Hebei Senlang Biotechnology Co., Ltd. to obtain an exclusive license for Senlang's CD7-targeted lentiviral vector platform and associated in.....
Subscribe for Full Access!
Gain valuable sourcing and trade intelligence from our database of millions of data points spanning 20+ years!
